42.60
1.11 (2.68%)
| Penutupan Terdahulu | 41.49 |
| Buka | 41.70 |
| Jumlah Dagangan | 510,302 |
| Purata Dagangan (3B) | 537,046 |
| Modal Pasaran | 2,049,888,256 |
| Harga / Jualan (P/S) | 464.82 |
| Harga / Buku (P/B) | 4.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | 31.01% |
| Margin Operasi (TTM) | 29.97% |
| EPS Cair (TTM) | 0.070 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.84% |
| Nisbah Semasa (MRQ) | 16.10 |
| Aliran Tunai Operasi (OCF TTM) | 69.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 52.09 M |
| Pulangan Atas Aset (ROA TTM) | 23.07% |
| Pulangan Atas Ekuiti (ROE TTM) | 34.38% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Maze Therapeutics, Inc. | Menaik | - |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.13 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 5.91% |
| % Dimiliki oleh Institusi | 92.25% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Trv Gp Iv, Llc | 30 Sep 2025 | 6,073,958 |
| Arch Venture Management, Llc | 30 Sep 2025 | 4,120,053 |
| A16z Capital Management, L.L.C. | 30 Sep 2025 | 1,702,225 |
| Matrix Capital Management Company, Lp | 30 Sep 2025 | 1,653,684 |
| Logos Global Management Lp | 30 Sep 2025 | 1,227,300 |
| General Catalyst Group Management, Llc | 30 Sep 2025 | 1,035,910 |
| Trv Gp V, Llc | 30 Sep 2025 | 950,800 |
| Casdin Capital, Llc | 30 Sep 2025 | 758,857 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (HC Wainwright & Co., 40.85%) | Beli |
| Median | 37.00 (-13.15%) | |
| Rendah | 34.00 (Guggenheim, -20.19%) | Beli |
| Purata | 43.17 (1.34%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 30.74 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 04 Dec 2025 | 55.00 (29.11%) | Beli | 42.60 |
| HC Wainwright & Co. | 03 Dec 2025 | 60.00 (40.85%) | Beli | 41.49 |
| 18 Sep 2025 | 50.00 (17.37%) | Beli | 23.48 | |
| Wedbush | 07 Nov 2025 | 36.00 (-15.49%) | Beli | 28.60 |
| JP Morgan | 29 Sep 2025 | 37.00 (-13.15%) | Beli | 25.20 |
| Guggenheim | 15 Sep 2025 | 34.00 (-20.19%) | Beli | 23.25 |
| BTIG | 12 Sep 2025 | 37.00 (-13.15%) | Beli | 23.30 |
| 11 Sep 2025 | 37.00 (-13.15%) | Beli | 24.80 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |